| Peptide reactivity (number of tested peptides) | | |
---|
Patient ID | Prevaccination | Postvaccination | TTP (wks) | Survival (wks) |
---|
MR-1 | a10/15b | 7/13 (2)c | 7 | 31 |
MR-2 | 12/16 | 15/17 (11) | 23 | 79 |
MR-4 | 13/14 | 15/17 (7) | 35 | 68 |
MR-5d | 3/14 | 15/15 (11) | 7 | 76 |
MR-6d | 8/16 | 3/17 (1) | 6 | 18 |
MR-7d | 2/16 | 5/15 (5) | 28 | 84 |
MR-9 | 3/18 | 4/17 (1) | 39 | 79 |
MR-10 | 16/19 | 13/19 (0) | 23 | 55 |
MR-11 | 7/17 | 7/15 (3) | SD (7)e | 17 |
MR-13 | 13/18 | 13/18 (4) | 33 | 104 (alive) |
MR-14 | 9/19 | 17/19 (9) | 35 | 107 |
MR-15 | 6/19 | 15/19 (8) | SD (131)e | 151 (alive) |
Immune response rate (%) | 100f | 100 (75)f | | |
Clinical response (wks) | | | 25.5g | 77.5g |
- TTP, time to progression; SD, stable disease.
- aNumbers of peptides to which reactivity was observed (>10 spots above background).
- bNumbers of peptides tested (survivin, cyclin D1, adipophilin, c-MET, vimentin, PRUNE2, VEGF, NY-ESO, MMP7, TYMS, IGF-BP3, RGS-5, CA IX, CP,TIF-1, ORMDL3, CLIC1, ELAC2 and PIG-10).
- cNumbers of peptides (in bold) to which a greater-than-two-fold increase after versus before vaccination was detectable.
- dShort protocol of vaccination starting with the middle dose of 107 vaccine cells.
- eSD (7) and SD (131) indicate stable disease at wks 7 and 131, respectively.
- fPatients reacting to more than one peptide in %.
- gMedian PD and median survival in weeks.